Fig. 3.
a The cost-effectiveness acceptability curve. QALY quality-adjusted life-year. b Probability of cost-effectiveness of nivolumab versus docetaxel at different drug costs of nivolumab. Blue dotted lines represent the WTP threshold of US$63,564/QALY for affluent regions, orange dotted lines represent the WTP threshold of $28,899/QALY for general regions and $63,564/QALY. QALY quality-adjusted life years, WTP willingness-to-pay